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Porcine reproductive and respiratory syndrome (PRRS) is 
caused by porcine reproductive and respiratory syndrome virus 
(PRRSV). PRRS is a widespread disease affecting domestic pigs, 
and is. considered one of the most economically significant 
diseases in the global swine industry.1 In 2005, the annual costs 
of PRRS for the American swine industry were approximately 
560 million dollars. 2, 3 Although vaccines are used to treat 
PRRSV, genetic diversity of PRRSV reduces the effectiveness of 
vaccines and contributes to PRRSV persistence in the field. 
There is an urgent need for alternate strategies to reduce the 
economic burden of PRRS.  An alternative strategy is the 
development of potent antiviral drugs. Unlike vaccines, antiviral 
drugs can provide almost immediate treatment for animals. The 
antiviral drugs can also be used in periods of increased 
susceptibility. A few natural products have been reported to 
significantly inactivate the PRRS virus. Their structures are 
depicted in Figure 1. 
Atractylodinol (1) and Ethoxysanguinarine (2) were reported 
as anti-PRRSV drugs by Li with IC50 values of 7.9 and 39.4 
μmol/L, respectively.4 Atractylodinol was isolated from rhizomes 
of Atractylodes lancea. A. lancea and is widely used in 
traditional Chinese and Japanese medicines against rheumatic 
diseases, digestive disorders, night blindness, and influenza.5 The 
reported isolation procedure gives 9.6 mg of impure 1 from 570 g 
of dried and powered A. lancea rhizomes.5 The low natural 
abundance inhibits future biological activity tests in animals. A 
patent using cobalt-complexed acetylenes to prepare dienediynes 
was reported in 2016.6 The related hydrocarbon analog 
atractylodin was synthesized using a bis-silylated diacetylene.7 
In our synthetic plan, coumpond 1 could be synthesized by 
coupling reaction of furyl enyne 4 and bromo alcohol 6. Enyne 4 
could be converted by a Corey-Fuchs reaction8 from 
commercially available 3-(2-furyl)acrolein (3). Compound 6 is 
accessible through unsaturated aldehyde 5. 
Commercially available 3-(2-furyl)acrolein 3 was subjected to 
the Corey-Fuchs protocol as shown in Scheme 1 to obtain the 
termianl alkyne 4 in 67% overall yield. Treatment of unsaturated 
aldehyde 5 (generated from cis-butenediol in two steps)9 with 
carbon tetrabromide and tripehnylphosphine afforded a 1,1-
dibromoalkene. Treatment of the 1,1-dibromoalkene with tetra-n-
butylammonium fluoride in THF at 45 °C resulted in both 
deprotection of the TBS group and the elimiation of bromide to 
make alcohol 6 in 66% yield.10  
With the two coupling components in hand, we focused on 
finding the most suitable coupling condition. After several 
modifications, utilizing a copper (I) catalyst with ethylamine and 
hydroxylamine hydrochloride in methanol, the Cadiot–
Chodkiewicz coupling reaction of compounds 4 and 6 furnished 
the desired natrual product 1 in 25% isolated yield.10 Although 
the yield was modest for the final step, it was the only effective 
conditions that we found for this two- component coupling. With 
the possible exception of the recent patent, no total synthesis 
route of atractylodinol had been reported in the literature. Despite 
the modest yield of the coupling reaction, the overall yield from 
commercially available materials was 11%.  
To improve the synthetic route for natrual product 1, as well 
as to make analog 8, we designed an alternate route as shown in 
Scheme 2.  Oxidation with manganese dioxide followed in situ 
by a Wittig reaction with (carbethoxymethylene)triphenyl-
phosphorane converted propargyl alcohol to the terminal 
acetylene in one pot in 45% yield after flash column 
chromatography purification. The iodoacetylene 7 was made 
from the terminal alkyne using morpholine hydroiodide salt and a 
catalytic amount of copper iodide.11, 12. The copper catalyzed 
coupling reaction between 4 and 7 gave the target molecule ester 
8 in 35% yield. 
It only took five steps to prepare compound 8 from 
commercially available materials. Compound 8 could be 
converted to natrual product 1 by reduction. 
The antiviral activity of compounds 1, 4, and 8 was evaluated 
in vitro using 10 μg of each compound and 102 focus forming 
units (FFU) of PRRSV strain NVSL97-7895. DMSO was used as 
a control. The compound plus virus mixtures were incubated at 
37° for one hour, and then inoculated in triplicate onto MARC-
145 cells. At 24 hours post infection, cells were fixed and 
immunocytochemistry performed to detect foci of PRRSV-
infected cells. Virus inhibition was calculated as the percent 
reduction in FFU in compound-treated wells compared to virus-
only control wells. The percent virus inhibition (PVI) for 
compound 1 was 100.0±0.7%, which demonstrates that our 
synthetic compound 1 is effective towards PRRSV as was 
reported. The PVI of compounds 4 and 8 were 93.4±4.0% and 
99.3±0.7%, respectively. The DMSO had little to no inhibitory 
effect on PRRSV, with PVI of 0.78±14.3%, indicating the 







Figure 1.  Natural product inhibitors of PRRSV 
 
Scheme 1. Total synthesis of atractylodinol. 
 
 
Scheme 2. Alternate synthetic route. 
 3 
 
Atractylodinol (1) was successfully synthesized in seven steps 
and all the characterization spectra (NMR and MS) of final 
product were identical to the litrature spectra. One more efficient 
six-step synthetic route through ethyl ester 8 was also reported. 
To the best of our knowledge, neither of these two efficient 
synthetic routes have been reported. 
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portions over 3 minutes. The color of solution changed to dark 
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argon gas protection. Acrolein 3 (0.489 g, 4 mmol) was added to 
the resulting solution over 5 minutes portionwise. After another 30 
minutes stirring at 0 °C, TLC was checked to make sure the 
reaction was done. Evaporation of CH2Cl2, followed by a quick 
flash column chromatography (silica gel, EtOAc:hexanes 1:1) to 
remove most of salt gave a pale grey crude solid product. The 
purification of crude product by flash column chromatography 
(silica gel, EtOAc:hexanes 1:4) affored dibromo compound as a 
light yellow solid in 77% yield; 1H NMR (300 MHz, CDCl3) δ = 
7.47–7.40 (m, 1H), 7.02 (dd, J = 10.4, 0.5 Hz, 1H), 6.68 (dd, J = 
15.5, 10.4 Hz, 1H), 6.54–6.36 (m, 3H). 
To a solution of prepared dibromo compound (0.560 g, 2.02 
mmol) in 15 mL THF, n-BuLi (2.5 M in hexane, 1.62 mL, 4.03 
mmol) was added dropwise over 10 minutes at -78 °C under argon 
protection. The resulting mixture stirred at -78 °C for 1 h, the the 
temperature was increased to rt. After 1 h stirring at rt, saturated 
NH4Cl aqueous solution was added slowly to quench the reaction. 
The reaction mixture was extracted with diethyl ether (3 x 30 mL). 
The organic layers were collected, dried with anhydrous MgSO4, 
filtered and concentrated in vacuo. The residue was purified by 
flash column chromatography (pentane) to affored 4 as colorless 
oil in 86% yield; 1H NMR (300 MHz, CDCl3) δ = 7.38 (d, J = 1.8 
Hz, 1H), 6.78 (d, J = 16.1 Hz, 1H), 6.45 – 6.31 (m, 2H), 6.03 (d, J 
= 18.4 Hz, 1H), 3.09 (d, J = 2.4 Hz, 1H). 13C NMR (75 MHz, 
CDCl3) δ = 152.0, 143.4, 130.3, 112.1, 110.7, 105.3, 83.0, 80.3. 
14. Experimental procedure for the synthesis of (E)-5-Bromopent-2-
en-4-yn-1-ol (6): Dibromo Compound was prepared by using 
previous described procedure for compound 4 in 96% yield; 1H 
NMR (300 MHz, CDCl3) δ = 6.96 (d, J = 10.3 Hz, 1H), 6.42–6.26 
(m, 1H), 6.14–6.00 (m, 1H), 4.00 (d, J = 7.8 Hz, 2H), 0.91 (s, 9H), 
0.08 (d, J = 7.5 Hz, 3H). 
To a solution of the dibromoalkene obtained above (0.383 g, 1.08 
mmol) in THF was added TBAF (1.0 M solution in THF, 0.4 mL, 
0.4 mmol) at rt, then the mixture was stirred at 45 °C for 18 h and 
diluted with Et2O. The mixture was washed with saturated NH4Cl, 
H2O, and brine and then dried over MgSO4. Concentration gave 
the mixture of the corresponding TBS- deprotected 
bromoacetylene 6; 1H NMR (300 MHz, CDCl3) δ = 6.38–6.23 (m, 
1H), 5.72 (dt, J = 15.9, 1.9 Hz, 1H), 4.20 (dd, J = 5.0, 1.9 Hz, 2H). 
15. Atractylodinol (1): To a solution of EtNH2 (70% aqueous 
solution, 2.2 mL) in MeOH (3 mL) was added CuCl (13.0 mg, 
131.4 μmol) at rt that resulted in the formation of a blue solution. 
To the resulting mixture was added NH2OH·HCl (54.8 mg, 0.788 
mmol) at room temperature to discharge the blue color. The 
resulting colorless solution indicated the presence of Cu(I) salt. To 
the resulting mixture was added 4 (108.6 mg, 0.920 mmol) in 
MeOH (2 mL) at rt, and the mixture was stirred at rt for 10 min 
that resulted in the formation of a yellow suspension. To the 
resulting mixture was added bromoacetylene 6 (42.3 mg, 0.263 
mmol) in MeOH (2 mL) at −78 °C, and mixture was stirred at the 
same temperature for 30 min. The mixture was allowed to warm to 
rt for 3 h. The mixture was diluted with Et2O, washed with H2O 
and brine, and then dried over MgSO4. Concentration and flash 
column chromatography (silica gel, EtOAc:hexanes 1:4) gave the 
corresponding product 1; 1H NMR (300 MHz, CDCl3) δ = 7.39 (s, 
1H), 6.81 (d, J = 16.0 Hz, 1H), 6.41 (dt, J = 11.1, 4.5 Hz, 3H), 
6.11 (d, J = 15.9 Hz, 1H), 5.88 (d, J = 15.9 Hz, 1H), 4.26 (d, J = 
3.3 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ = 152.0, 145.4, 143.9, 
131.3, 112.4, 111.6, 109.3, 104.8, 81.3, 81.1, 77.1, 75.0, 63.0.  
16. Antiviral Activity Compounds were diluted in DMSO and 
screened for anti-PRRSV activity using a focus-reduction assay 
adapted from Wu et al.13 Briefly, MARC-145 cells were seeded at 
3x105 cells/well in a 12-well plate 24 hours prior to the anti-viral 
assay, and media changed to 1 ml/well directly before infection. 
For each compound, 35 μg  (35 μl) was added to 700 focus-
forming units (FFU) of PRRSV in a volume of 1.2 ml (incubation 
volume), for an incubation concentration of 29.17 μg/ml of the 
compound. In addition, a virus-only sample with 700 FFU PRRSV 
in 1.2 ml media was used as a control. The virus-compound 
mixtures and virus-only control were incubated at 37° for one 
hour. Samples were brought to a total volume of 3.5 ml, and 1 ml 
was inoculated per well in triplicate, resulting in each well 
containing 10μg compound and 200 FFU in a well volume of 2 ml 
for a final well concentration of 5 μg/ml of compound. The plates 
were incubated at 37° supplemented with 5% CO2. At 24 hours 
post infection, cells were fixed in ice-cold methanol:acetone and 
immunocytochemistry performed using the PRRSV N protein 
specific monoclonal antibody SDOW17 (Rural Technology) as the 
primary antibody and sheep anti-mouse IgG conjugated to HRP 
(Jackson ImmunoResearch) as the secondary antibody. Following 
addition of the HRP substrate, cells were rinsed with distilled 
water, air-dried, and foci of infected cells enumerated by light 
microscopy. Percent virus inhibition was calculated compared to 
virus-only control wells. Standard deviations were calculated 
using the means of repeated experiments. 
 
 
Figure 2. Antiviral activity was tested using 10 ug of each 
compound against 10
2
 FFU PRRSV. Percent virus inhibition 
is reported as the mean percent reduction in compound-
treated wells compared to virus-only control wells. Error 
bars represent ±one standard deviation of the mean of 
replicates. 
